Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.
Snohomish, WA - Johnson’s Junk Removal is expanding access to professional junk removal services in Kenmore with the official launch of its full-service solutions, now available through its local service page at junk removal in Kenmore . The expansion brings reliable, locally owned junk hauling, cleanouts, and light demolition services to homeowners and businesses seeking fast, responsible, and affordable solutions.
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (NYSE: ABBV) was in advanced discussions
Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.
In a landmark achievement for computational medicine, researchers at Harvard Medical School have developed a "generalist" artificial intelligence model that is fundamentally reshaping the landscape of oncology. Known as the Clinical Histopathology Imaging Evaluation Foundation (CHIEF), this AI system has demonstrated a staggering 98% accuracy in diagnosing rare and metastatic cancers, while simultaneously predicting patient [...]
As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence infrastructure captured the lion's share of investor attention, the healthcare sector has emerged as the unexpected powerhouse
As of December 26, 2025, Baxter International Inc. (NYSE: BAX) stands at a pivotal crossroads in its nearly century-long history. Long considered a defensive "blue-chip" staple of the healthcare sector, Baxter spent much of the early 2020s grappling with the massive debt from its $10.5 billion acquisition of Hillrom, supply chain fragilities exposed by the [...]
The highly anticipated "Santa Claus Rally" of 2025 has officially failed to materialize, leaving investors with a lump of coal as they ring in the new year. While the broader market enjoyed a year of respectable double-digit gains, the traditional seven-session window—encompassing the last five trading days of December
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s (IRA) negotiation provisions. This milestone represents a fundamental shift in the federal government’s role in drug
Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company’s common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026.
Johnson & Johnson is nearing its 52-week high, driven by strong momentum and positive news, raising expectations for its upcoming earnings report amidst heightened sensitivity to market trends.
As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity epidemic—and companies grappling with the first real bite of the Inflation Reduction Act (IRA). While the healthcare
As the final closing bell of 2025 rings on Wall Street, the S&P 500 (SPX) stands on the precipice of history. After a year defined by a "triple-tailwind" of aggressive Federal Reserve easing, a fundamental shift in the artificial intelligence revolution, and surprisingly resilient corporate earnings, the benchmark index
Palantir Technologies (NYSE: PLTR) saw its shares slide in after-hours trading on Tuesday, December 30, 2025, as a combination of hawkish signals from the Federal Reserve and aggressive year-end profit-taking by institutional investors dampened the holiday spirit on Wall Street. The stock, which has been a titan of the 2025
As the final trading days of 2025 unfold, the financial markets are witnessing a phenomenon that analysts have dubbed the "Great Rebalancing." While the S&P 500 is poised to finish the year with impressive gains of nearly 19%, the final week of December has been marked by uncharacteristic turbulence
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally stabilizing and corporate balance sheets bulging with record-breaking liquidity, the stage is set for a massive wave of
In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV) today, December 30, 2025. The investment firm, which operates a unique hybrid model of investigative journalism and hedge
The financial markets are closing out 2025 in a state of high-octane paradox. The iShares Core S&P 500 ETF (NYSE Arca: IVV), the massive exchange-traded fund that serves as a cornerstone for millions of retirement portfolios, is currently navigating a treacherous "Scrooge" dip following a year of relentless record-breaking.
